Generate an explanation for the given claim using the provided supporting material from the paragraph. Please consider the following points while generating an output. 1) The claim will always have supporting proof in the paragraph, and the paragraph will have a clear point of view supporting the claim. 2) There can be instances where direct correlation to the claim is not available. Make use of the sentences in the paragraph to provide a corresponding output supporting the claim. 3) The explanation should be at least one and at most twelve sentences long.

[Q]: Paragraph: The new drugs, which have not been detailed to investors, will include cancer and respiratory disease medicines, the newspaper said on its website. (link.reuters.com/fup56v) Britain's biggest drugmaker is also expected to report that fourth-quarter sales in China, where it is embroiled in a major bribery probe, took a smaller hit than when the scandal first blew up during the summer quarter, the report said. The investigation began in July 2013, after Chinese police accused GSK of funneling up to 3 billion yuan ($495.05 million) to travel agencies to facilitate bribes to boost its drug sales. ($1 = 6.0600 Chinese yuan) Claim: GSK to launch late-stage clinical trials on 10 new drugs: paper.
[A]: GlaxoSmithKline is set to unveil plans to launch late-stage clinical trials on 10 new drugs over the next two years, the Telegraph reported, without citing sources.

[Q]: Paragraph: "The story states that US sales for the product hit $99 million in 2008. But it never explained the cost to the individual. The study ""found no effect,"" the story states succinctly. The story said the researchers found the product to be safe. But it could have mentioned that the National Center for Complementary & Alternative Medicine states ""Side effects of ginkgo may include headache, nausea, gastrointestinal upset, diarrhea, dizziness, or allergic skin reactions. More severe allergic reactions have occasionally been reported."" Although the discussion was brief, it did refer to the study as ""properly designed"" and ""placebo controlled."" There was no disease-mongering of dementia or cognitive decline. 3 short quotes with different perspectives, presented in balance. In a story based on a study that pokes holes in some peoples' beliefs about a product to prevent cognitive decline, there could have been at least one line about other research into cognitive decline. The widespread use of the product is clear in the story. The story states that the product has been in use for more than 500 years. We can't be sure of the extent to which the story was influenced by a news release. it apparently did lift one quote from a news release/statement." Claim: Study: Ginkgo biloba has no effect on Alzheimer's, dementia
[A]: In fewer words than its HealthDay competitor (404 words vs. 740), this story did a slightly better job on providing context and balance. Americans spend about $100 million a year on this stuff.

[Q]: Paragraph: Tuesday's unanimous jury decision in San Francisco federal court was not a finding of Bayer's liability for the cancer of plaintiff Edwin Hardeman. Liability and damages will be decided by the same jury in a second trial phase beginning on Wednesday. Bayer, which denies allegations that glyphosate or Roundup cause cancer, said it was disappointed with the jury's initial decision. Bayer acquired Monsanto, the longtime maker of Roundup, for $63 billion last year. Bayer shares were 12.5 percent lower at 1110 GMT, the biggest intraday loss in 16 years, wiping some 8 billion euros ($9.1 billion) off its valuation. "This looks like 2-0 plaintiffs, and clearly not helpful for the overall payout calculus and resolution of the litigation," said Bernstein analyst Gunther Zechmann. Glyphosate is the world's most widely used weed killer. Monsanto's Roundup was the first glyphosate-based weed killer but is no longer patent-protected and many other versions are now available. Bayer does not provide sales figures for the product. "We are confident the evidence in phase two will show that Monsanto's conduct has been appropriate and the company should not be liable for Mr. Hardeman's cancer," the company said. The case was only the second of some 11,200 Roundup lawsuits to go to trial in the United States. Another California man was awarded $289 million in August after a state court jury found Roundup caused his cancer. That award was later reduced to $78 million and is on appeal. Baader Helvea analyst Markus Mayer noted that Bayer management announced ambitious targets in December. "(It) is now under pressure to deliver and trying to avoid becoming a target for activist or strategic buyers." Activist investor Elliott already holds a stake of less than 3 percent in Bayer, Reuters disclosed last year. Brokerage Warburg lowered its recommendation to "Hold" from "Buy", arguing that the with the renewed setback upcoming glyphosate court cases would remain a drag on the share price. Bayer had claimed that jury was overly influenced by plaintiffs' lawyers allegations of corporate misconduct and did not focus on the science. U.S. District Judge Vince Chhabria called such evidence "a distraction" from the scientific question of whether glyphosate causes cancer. He split the Hardeman case into two phases: one to decide causation, the other to determine Bayer's potential liability and damages. Under Chhabria's order, the second phase would only take place if the jury found Roundup to be a substantial factor in causing Hardeman's non-Hodgkin's lymphoma. The jury found that it was on Tuesday. Union Investment fund manager Markus Manns cautioned that it was too early to read anything into individual rulings in courts of first instance. "What will be important for Bayer is the outcome of the appeals hearings," he told Reuters, adding that Bayer should not yet engage in settlement talks. Chhabria has scheduled another bellwether trial for May and a third trial is likely to take place this year. All three cases will be split into causation and liability phases. The U.S. Environmental Protection Agency, the European Chemicals Agency and other regulators have found that glyphosate is not likely carcinogenic to humans. But the World Health Organization's cancer arm in 2015 reached a different conclusion, classifying glyphosate as "probably carcinogenic to humans." Claim: Bayer shares slide after latest Roundup cancer ruling.
[A]:
Shares in Germany's Bayer's fell more than 12 percent on Wednesday after a second U.S. jury ruled its Roundup weed killer caused cancer.